Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”We are absolutely thrilled to share that the OCEANIC-STROKE trial has successfully met its primary efficacy and safety endpoints.
These landmark findings validate our ability to uncouple pathological thrombus formation from hemostasis—a breakthrough that has the potential to have far more reaching impact in the medical care of patients with cardiovascular disease.
Asundexian now emerges as an established treatment option addressing a major unmet need among the approximately 5 million people worldwide who experience a new non-cardioembolic ischemic stroke each year.
We are profoundly grateful for our partnership with Bayer and for the invaluable contributions of our global network of investigators and study teams whose dedication made OCEANIC-STROKE possible.”
Read the full article here.
Stay updated with Hemostasis Today.
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week
-
Oct 4, 2026, 13:45Suswapna Singh Rawat: The Clinical Significance of Coronary Plaque Stability